Opioid Rotation in Renal Failure with Myoclonus
Mr. L is 71 with metastatic pancreatic cancer and eGFR 22 mL/min/1.73m2. He has been on oral hydromorphone 4 mg every 4 hours plus 4 mg breakthrough doses (about 6 breakthrough doses daily) for 3 weeks. Over 48 hours he develops diffuse myoclonus, increasing drowsiness between doses, and reports pain 7/10 despite the regimen. His family asks whether he is 'dying now' and wants him kept comfortable. He is alert enough to state he wants to be awake to speak with his brother arriving in two days. The nurse reports he has not had a bowel movement in 5 days; abdomen is soft, non-tender, bowel sounds present. No fever, no new neurologic deficit, pupils 3 mm and reactive.
1. Is this opioid toxicity, progression, or something else? What is your immediate assessment and management plan?
Read the worked answer
The combination of myoclonus, sedation between doses, and uncontrolled pain on a high-dose opioid in a patient with eGFR 22 points strongly to accumulation of hydromorphone metabolites (hydromorphone-3-glucuronide is renally cleared and is neuroexcitatory). This is not simply 'dying' and not purely disease progression, though progression may be contributing. Constipation is a reversible contributor to both myoclonus and sedation and must be addressed concurrently.
Immediate steps:
- Reduce or hold the offending opioid rather than escalating it; escalating would worsen neuroexcitation.
- Rotate to an opioid less dependent on renal clearance. Fentanyl (transdermal or parenteral) or, with caution, low-dose methadone are reasonable; morphine and hydromorphone should be avoided. If using fentanyl, calculate an equianalgesic starting dose conservatively (reduce by 25-50% for incomplete cross-tolerance) and titrate.
- Treat constipation aggressively (oral or rectal laxatives, consider disimpaction if fecal loading).
- Consider low-dose benzodiazepine or clonazepam only if myoclonus is distressing and persists after opioid adjustment.
- Reassess every few hours; document goals (he wants to be awake for his brother).
- Explain to the family that this is likely a reversible medication effect, not imminent death, and set expectations about the next 48 hours.
2. The family asks whether to start a subcutaneous infusion now. How do you decide route and how do you counsel them?
Read the worked answer
Route should follow the goal of comfort plus the patient's stated wish to be alert. A subcutaneous infusion (e.g., fentanyl or methadone via syringe driver) provides steady levels and avoids peaks that drive sedation and myoclonus, and it is appropriate when oral intake is unreliable or when frequent dosing is needed. However, starting an infusion is not itself a 'comfort care only' decision; it is a delivery method.
Counseling points:
- The infusion replaces erratic peak-and-trough dosing with a steady level, which may actually make him more awake, not less.
- We will continue to treat breakthrough pain and monitor for oversedation.
- The myoclonus should improve as the hydromorphone clears; this may take 24-72 hours.
- We will reassess in the morning and adjust; the plan is revisable.
- Clarify that the goal is comfort AND alertness for his brother's visit, and that these are usually compatible with better opioid selection.
Document the conversation, the equianalgesic calculation, and the reassessment plan. Involve palliative care if available.